, Tracking Stock Market Picks
Enter Symbol:
Auxilium Pharmaceuticals, Inc. (AUXL) [hlAlert]

up 59.18 %

Auxilium Pharmaceuticals, Inc. (AUXL) rated Buy with price target $35 by UBS

Posted on: Monday,  Mar 3, 2014  1:25 PM ET by UBS

UBS rated Buy Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 03/03/2014. Previously UBS rated Buy Auxilium Pharmaceuticals, Inc. (NASDAQ: AUXL) on 04/15/2011.,
when the stock price was $22.91. Since then, Auxilium Pharmaceuticals, Inc. has gained 59.19% as of 01/29/2015's recent price of $36.47.
If you would have followed the previous UBS's recommendation on AUXL, you would have gained 59.18% of your investment in 1385 days.

Auxilium Pharmaceuticals, Inc. is a specialty pharmaceutical company that develops and markets products for urology and sexual health. Auxilium markets Testim 1%, a topical testosterone gel, for the treatment of hypogonadism. Auxilium is developing additional Testim line extensions, as well as other products for urology and sexual health, including an enzyme in Phase II for the treatment of Peyronie's Disease that may also prove useful for the treatment of Dupuytren's Disease.

UBS is the leading global wealth manager, a top tier investment banking and securities firm, and one of the largest global asset managers. In Switzerland, UBS is the market leader in retail and commercial banking. With headquarters in Zurich and Basel, Switzerland, UBS operates in over 50 countries and from all major international centers. UBS employs more than 80,000 people.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/3/2014 1:25 PM Buy
30.75 35.00
as of 10/17/2014
1 Week down  -3.58 %
1 Month down  -1.76 %
3 Months up  58.29 %
1 YTD up  47.75 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
1/17/2014 11:25 AM Buy
24.71 30.00
8/2/2013 2:25 PM Buy
19.21 23.00
4/30/2013 10:25 AM Buy
14.27 20.00
8/21/2012 11:25 AM Buy
23.28 34.00
11/1/2011 12:25 PM Buy
14.82 27.00
4/15/2011 11:25 AM Buy
22.91 30.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy